New pill for stubborn hives shows promise, but trial halted early
Symptom relief
Terminated
This Phase 2 trial tested an experimental drug called EP262 in 113 people with chronic spontaneous urticaria (long-lasting hives with no clear cause). Participants took either EP262 or a placebo daily for 6 weeks, while continuing their usual antihistamines. The study aimed to se…
Phase: PHASE2 • Sponsor: Escient Pharmaceuticals, Inc • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC